Recent development of monoamine oxidase inhibitors

Bibliography

• SINGER TP, VON KORFF RW, MURPHY DL: In: Monoamine Oxidase: Structure, Function and Altered Functions. Academic, New York, USA (1979).
   Google Scholar
• MURE M, MILLS SA, KLINMAN JP: Catalytic mechanism of the topa quinone containing copper amine oxidases. Biochemistry (2002) 41(30):9269–9278.
   PubMedGoogle Scholar
• JOHNSTON JP: Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. (1968) 17:1285–1297.
   PubMed Web of Science ®Google Scholar
• KNOLL J, MAGYAR K: Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol (1972) 5:393–408.
   PubMedGoogle Scholar
• BACH AW, LAN NC, JOHNSON DL et al.: cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. USA (1988) 85:4934–4938.
   PubMed Web of Science ®Google Scholar
• WOUTERS J: Structural aspects of of monoamine oxidase and its reversible inhibition. Curr. Med. Chem. (1998) 5:137–162.
   PubMed Web of Science ®Google Scholar
• WALKER MC, EDMONDSON DE: Structure-activity relationships in the oxidation of benzylamine analogues by bovine liver mitochondrial monoamine oxidase B. Biochemistry (1994) 33:7088–7098.
   PubMed Web of Science ®Google Scholar
• MILLER JR, EDMONDSON DE: Structure-activity relationships in the oxidation ofpara-substituted benzylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry (1999) 38:13670–13683.
   PubMedGoogle Scholar
• SILVERMAN RB, HOFFMAN SJ, CATUS WB: A mechanism for mitochondrial monoamine oxidase catalyzed amine oxidation. J. Am. Chem. Soc. (1980) 102:7126–7128.
   Web of Science ®Google Scholar
• KIM JM, BOGDAN MA, MARIANO PS: Mechanistic analysis of the 3-methyllumiflavin-promoted oxidative deamination of benzylamine. A potential model for monoamine oxidase catalysis. J. Am. Chem. Soc. (1993) 115:10591–10595.
   Google Scholar
• LUX, RODRIGUEZ M, GU W, SILVERMAN RB: Inactivation of mitochondrial monoamine oxidase B by methylthio-substituted benzylamines. Bioorg-. Med. Chem. (2003) 11(20):4423–4430.
   PubMedGoogle Scholar
• CESURA AM, PLETSCHER k The newgeneration of monoamine oxidase inhibitors. Prog-. Drug Res. (1992) 38:171–257.
   PubMedGoogle Scholar
• SAURA J, LUQUE JM, CESURA AM et al.: Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience (1994) 62:15–30.
   PubMed Web of Science ®Google Scholar
• AMREIN R, MARTIN JR, CAMERON AM: Moclobemide in patients with dementia and depression. Adv. Neurol (1999) 80:509–519.
   PubMedGoogle Scholar
• CHIBA K, TREVOR A, CASTAGNOLI N: Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. (1984) 120:574–578.
   PubMed Web of Science ®Google Scholar
• FRITZ RR, ABELL CW, PATEL NT, GESSNER W, BROSSI A: Metabolism of the neurotoxin in MPTP by human liver monoamine oxidase B. FEBS Lett. (1985) 186:224–228.
   PubMedGoogle Scholar
• GRIMSBY J, TOTH M, CHEN K a/.:Increased stress response and 13-phenylethylamine in MAOB-deficient mice. Nat. Genet. (1997) 17:206–210.
   Google Scholar
• DE ZUTTER GS, DAVIS RJ: Pro -apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc. Natl. Acad. Sci. USA (2001) 98:6168–6173.
   PubMed Web of Science ®Google Scholar
• MCMILLAN FH, LEONARD F, MELTZER RI, KING JA: Antitubercular substances. II. Substitution products of isonicotinic hydrazide. J. Am. Pharm. Assoc. (1953) 42:457–464.
   Google Scholar
• FOWLER CJ, ORELAND L, CALLINGHAM BA: The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications. J. Pharm. Pharmacol. (1981) 33:341–347.
   PubMed Web of Science ®Google Scholar
• KNOLL J, ECSERY Z, KELEMEN K, NIEVEL J, KNOLL B: Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch. Int. Pharmachodyn. Ther. (1965) 155:154–164.
   PubMedGoogle Scholar
• FINBERG J P, TENNE M, YOUDIM MB:Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br. J. Pharmacol. (1981) 73(1):65–74.
   PubMedGoogle Scholar
• WEINSTOCK M, BEJAR C, WANG RH et al.: TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J. Neural lransm. (2000) Supp1.60: 157–169.
   Google Scholar
• YOUDIM M B, HOLMAN B: The nature of inhibition of cat brain mitochondrial monoamine oxidase by clorgyline. J. Neural Tranm. (1975) 37(1):11–24.
   PubMedGoogle Scholar
• MOUREAU F, WOUTERS J, VERCAUTEREN DP et al.: A reversible monoamine oxidase inhibitor, toloxatone: structural and electronic properties. Eur. Med. Chem. (1992) 27:939–948.
   Google Scholar
• MOUREAU F, WOUTERS J, VERCAUTEREN DP et al.: A reversible monoamine oxidase inhibitor, toloxatone: spectrophotometric and molecular orbital studies of the interaction with flavin adenine dinucleotide (FAD). Eur. J. Med. Chem. (1994) 29:269–277.
   Web of Science ®Google Scholar
• MOUREAU F, WOUTERS J, DEPAS M et al.: A reversible monoamine oxidase inhibitor, toloxatone: comparison of its physicochemical properties with those of other inhibitors including brofaromine, harmine, R40519 and moclobemide. Eur. J. Med. Chem. (1995) 30:823–838.
   Google Scholar
• RABASSEDA X, SORBERA LA, CASTANER J: Befloxatone (MD-370503): antidepressant, MAO-A [monoamine oxidase A] inhibitor. Drugs Fut. (1999) 24:1057–1067.
   Google Scholar
• WOUTERS J, MOUREAU F, EVRARD G et al.: A reversible monoamine oxidase A inhibitor, befloxatone: structural approach of its mechanism of action. Bioorg-. Med. Chem. (1999) 7:1683–1693.
   PubMedGoogle Scholar
• BINDA C, NEWTON-VINSON P, HUBALEK F, EDMONDSON DE, MATTEVI A: Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol. (2002) 9:22-26. First report of the crystallised structure of the complex of MAO-B linked to pargyline.
   Google Scholar
• EDMONDSON D E, BINDA C, MATTEVI A: The FAD binding sites of human monoamine oxidases A and B. Neurotoxicology (2004) 25:63–72.
   PubMedGoogle Scholar
• DE COLIBUS L, LI M, BINDA C, LUSTIG A, EDMONDSON DE, MATTEVI A: Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. (2005) Proc. Natl Acad. Sci. USA 102(36):12684–12689.
   Google Scholar
• MA J, YOSHIMURA M, YAMASHITA E, NAKAGAWA A, ITO A. TSUKIHARA T: Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors. J. MoL Biol. (2004) 338:103–114.
   Google Scholar
• HUBALEK F, BINDA C, KHALIL A et ell.:Demonstration of isoleucine 199 as a structural determinant for selective inhibition of human monoamine oxidase B by specific reversibile inhibitors. J. Biol. Chem. (2005) 280(16):15761–15766.
   Google Scholar
• JONES TZ, FLEMING P, EYERMANN CJ, GRAVESTOCK MB, RAMSAY RR: Orientation of oxazilidinones in the active site of monoamine oxidase. Biochem. PharmacoL (2005) 70:407–416.
   PubMedGoogle Scholar
• FREDERICK R, NORBERG B, DURANT F, 00MS F, WOUTERS J: Three 5H-indeno [1,2-c] pyridazin-5-one derivatives, potent type-B monoamine oxidase inhibitors. Acta Crystallogr. C (2004) 60:623–626.
   Google Scholar
• FREDERICK R, 00MS F, CASTAGNOLI Jr N et al.: (E)-8-(3-Chlorostyry1)-1,3,7-trimethybiantine, a caffeine derivative acting both as antagonist of adenosine A. receptors and as inhibitor of MAO-B. Acta Crystallogr. C (2005) 61:531–532.
   Google Scholar
• BINDA C, HUBALEK F, LI M, HERZIG Y et al.: Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J. Med. Chem. (2004) 47:1767–1774.
   PubMed Web of Science ®Google Scholar
• GHANBARPOUR A, HADIZADEH F, PIRI F, RACHIDI-RANJBAR P: Synthesis, conformational analysis and antidepressant activity of moclobemide new analogues. Pharm. Acta Hely. (1997) 72:119–122.
   PubMedGoogle Scholar
• SCHLAEGER EJ, CHRISTENSEN K: Transient gene expression in mammalian cells grown in serum-free suspension culture. Cytotechnology (1988) 15:1–13.
   Google Scholar
• ZHOU M, PANCHUCK-VOLOSHINA N:A one-step fluorometric method for the continuous measurement of monoamine oxidase activity. Anal. Biochem. (1997) 253:169–174.
   PubMed Web of Science ®Google Scholar
• KIM H, SABLIN SO, RAMSAY RR: Inhibition of monoamine oxidase A by carboline derivatives. Arch. Biochem. Biophys. (1997) 337:137–142.
   PubMed Web of Science ®Google Scholar
• NELSON DL, HERBERT A. PETILLOT T, PICHAT L, GLOWINSKI J, HAMON M: PFIlHarmaline as a specific ligand of MAO A. I . Properties of the active site of MAO A from rat and bovine brains./ Neurochem. (1979) 32(0:1817–1827.
   Google Scholar
• BEMBENEK ME, ABELL CW, CHRISEY LA, ROZWADOWSKA MD, GESSNER W, BROSSI A: Inhibition of monoamine oxidases A and B by simple isoquinoline alkaloids: racemic and optical active 1,2,3,4-tetrahydro-,3,4-dihydro-, and fully aromatic isoquinoline. J. Med. Chem. (1990) 33:147–152.
   PubMedGoogle Scholar
• CESURA AIVI, BOS M, GALVA MD, IMHOF R, DAPRADA M: Characterization of the binding of PI-IlRo 41-1049 to the active site of monoamine oxidase-A. Molec. PharmacoL (1990) 37:358–366.
   PubMedGoogle Scholar
• CESURA A M, GALVA M D, IMHOF R, KYBURZ E, PICOTTI G B, DAPRADA M: PI-IlRo 19-6327: a reversible ligand and affinity-labeling probe for monoamine oxidase-B. Eur. J. PharmacoL (1989) 162:457–465.
   PubMedGoogle Scholar
• YOUDIM MB, BAR-AM 0, YOGEV-FALACH M et aL: Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J . Neurosci. Res. (2004) 79:172–179.
   Google Scholar
• YOUDIM MB, FRIDKIN M, ZHENG H: Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech. Ageing Dev. (2005) 126:317–326.
   PubMed Web of Science ®Google Scholar
• YOUDIM M B H, BUCCAFUSCO JJ: CNS target for multifunctional drugs in the treatment of Alzheimer's and Parkinson's disease. J. Neural Transm. (2005) 112:519–537.
   PubMedGoogle Scholar
• MANDEL S, WEINREB 0, AMIT T, YOUDIM MB: Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res. Rev. (2005) 48:379–387.
   PubMed Web of Science ®Google Scholar
• YOUDIM MB, BUCCAFUSCO JJ: Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends PharmacoL Sci. (2005) 26:27–35.
   PubMed Web of Science ®Google Scholar
• RANDO RR, EIGNER A: The pseudoirreversible inhibition of monoamine oxidase by allylamine. MoL PharmacoL (1977) 13:1005–1013.
   PubMed Web of Science ®Google Scholar
• SILVERAMN RB, HIEBERT CK, VASQUEZ ML: Inactivation on monoamine oxidase by allylamine does not results in flavin attachment. J. Biol. Chem. (1985) 260:14648–14652.
   PubMedGoogle Scholar
• BEY P, FOZARD J, LACOSTE JM, McDONALD IA, ZREIKA M, PALFREYMAN MG: (E)-2-(3,4-dimethoxypheny1)-3-fluoroallylamine: a selective, enzyme activated inhibitor of type B monoamine oxidase. J. Med. Chem. (1984) 27:9–10.
   PubMedGoogle Scholar
• CHRISTENSEN A V, FJALLAND B, PEDERSEN V, DANNESKIOLD-SAMSOEE P, SVENDSEN 0: Pharmacology of a new phthalane (Lu 10-171), with specific 5-HT uptake inhibiting properties. Eur. PharmacoL (1977) 41(2):153–62.
   PubMedGoogle Scholar
• SIEGMUND EA, CADMUS RA, LUG: Screening of analgesics including aspirin type compound based upon the antagonism of chemically induced writhing in mice. PharmacoL Exp. Therap. (1957) 119:421–425.
   Google Scholar